Company Profiles

driven by the PitchBook Platform

DNAtrix

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient's immune system to trigger an aggressive anti-tumor T-cell response.

2005

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$19.8M

Latest Deal Amount

$21.8M

Total Amount Raised

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient's immune system to trigger an aggressive anti-tumor T-cell response.

Website:

www.dnatrix.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

2450 Holcombe Boulevard Houston, TX 77021United States +1 (832) 930-2401
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore DNAtrix's full profile, request a free trial.

    DNAtrix Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    DNAtrix Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    DNAtrix Investors (11)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    CPRITOtherMinority000 0000000 0000
    JLABSAccelerator/IncubatorMinority000 0000000 0000
    Mercury FundVenture CapitalMinority000 0000000 0000
    Morningside GroupVenture CapitalMinority000 0000000 0000
    Targeted TechnologyVenture CapitalMinority000 0000000 0000
    CPRIT Other
    JLABS Accelerator/Incubator
    Mercury Fund Venture Capital
    Morningside Group Venture Capital
    Targeted Technology Venture Capital

    DNAtrix Executive Team (12)

    NameTitleBoard
    Seat
    Contact
    Info
    Frank Tufaro Ph.DChief Executive Officer & Board Member
    Brian MooneyChief Financial Officer
    Imran Alibhai Ph.DManaging Director & Senior Vice President, Business Development
    Imre Kovesdi Ph.DChief Scientific Officer & Senior Vice President, Research
    Erin Mitchell Ph.DVice President, Manufacturing & Director, Manufacturing
    Frank Tufaro Ph.D Chief Executive Officer & Board Member
    Brian Mooney Chief Financial Officer
    Imran Alibhai Ph.D Managing Director & Senior Vice President, Business Development
    Imre Kovesdi Ph.D Chief Scientific Officer & Senior Vice President, Research
    Erin Mitchell Ph.D Vice President, Manufacturing & Director, Manufacturing

    DNAtrix Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    Daniel Watkins Ph.DMercury FundCo-Founder & Partner000 0000
    Drew Pardoll Ph.DDNAtrixBoard Member000 0000
    Francis McCormickSelfBoard Member000 0000
    Frank Tufaro Ph.DDNAtrixChief Executive Officer & Board Member000 0000
    Reenie McCarthy JDMorningside GroupDirector000 0000
    Daniel Watkins Ph.D Co-Founder & Partner Mercury Fund
    Drew Pardoll Ph.D Board Member DNAtrix
    Francis McCormick Board Member Self
    Frank Tufaro Ph.D Chief Executive Officer & Board Member DNAtrix
    Reenie McCarthy JD Director Morningside Group
    Request full access to PitchBook